ABVC BioPharma Achieves $100,000 Licensing Milestone with ForSeeCon, Enhancing Ophthalmology Focus
ABVC BioPharma's recent $100,000 milestone payment from ForSeeCon Eye Corporation underscores the growing commercial interest in its ophthalmology solutions, particularly Vitargus®, and strengthens its position in the global eye care market.
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, has announced the receipt of a $100,000 milestone licensing payment from ForSeeCon Eye Corporation, marking a significant step in their collaboration to develop and commercialize drugs for ophthalmic indications. This payment brings ABVC's cumulative licensing revenue to $946,000, with the potential for the overall value of the agreement to reach up to $1.0 billion, including equity, royalties, and performance-based payouts.
The partnership focuses on Vitargus®, a next-generation vitreous substitute, targeting the rapidly expanding $110 billion global eye care market. Dr. Uttam Patil, ABVC's Chief Executive Officer, highlighted the importance of this milestone as it provides non-dilutive capital for further development and reflects the international interest in Vitargus®, especially from Europe and Japan. ForSeeCon's CEO, Jerry Chang, also expressed enthusiasm about the global response to Vitargus® and its potential to improve retinal surgery outcomes.
ABVC and ForSeeCon plan to initiate pivotal clinical trials in key international markets in 2025, supported by the latest payment and the momentum from multiple late-stage CNS licensing deals and expansion into oncology. With the global eye care market projected to grow at a compound annual growth rate of 6.9% from 2024 to 2030, ABVC reaffirms its commitment to capital-efficient innovation and global co-development partnerships to unlock the market potential of its product pipeline.
For more information on the global eye care market, visit https://www.grandviewresearch.com/horizon/outlook/eye-care-market-size/global?utm_source=chatgpt.com.